Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SIGA with free AI briefings, catalyst countdowns, and dilution alerts.

SIGA · SIGA TECHNOLOGIES INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$116.4M Cash on Hand
CF+ Cash Runway
Follow SIGA by email Get an email when SIGA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SIGA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tecovirimat (ST-246)
FDA approved Jul 2018 · Tpoxx
Smallpox Phase 4 · NCT04485039 Completed
Tecovirimat Monohydrate Smallpox Phase 4 · NCT04392739 Completed
MVA-BN Smallpox Vaccine Smallpox Phase 2 · NCT04957485 Active not recruiting
TPOXX IV (Tecovirimat Injection, 10 mg/mL) Orthopox Virus Infection N/A · NCT05380752 No longer available

Also used in these trials (approved or third-party drugs, not SIGA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Sucroferric Oxyhydroxide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SIGA holds $116.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SIGA files for a raise →

👥 Who Owns SIGA

Insiders 1.8% Institutions (218 holders) 47.5% Public and other holders 50.7%
HolderTypeShares% of sharesAs of
Daniel J Luckshire
Executive VP & CFO · +55,228 options
Insider 280,493 0.39% 2026-03-13
Joseph W III Marshall
Director · +34,169 options
Insider 246,523 0.34% 2026-06-09
Dennis E Hruby
EVP & Chief Scientific Officer · +54,942 options
Insider 198,537 0.28% 2026-03-13
Diem Nguyen
Chief Executive Officer, Director · +390,820 options
Insider 138,767 0.19% 2026-03-13
Jaymie A Durnan
Director · +34,169 options
Insider 88,754 0.12% 2026-06-09
Holly L. Phillips
Director · +34,169 options
Insider 73,754 0.10% 2026-06-09
Gary J. Nabel
Director · +34,169 options
Insider 73,754 0.10% 2026-06-09
Julian Nemirovsky
Director · +34,169 options
Insider 73,754 0.10% 2026-06-09
Larry R. Miller
General Counsel · +20,762 options
Insider 51,912 0.07% 2026-03-25
Harold Eugene Jr. Ford
Director · +34,169 options
Insider 47,538 0.07% 2026-06-09
Evan A. Knisely
Director · +19,084 options
Insider 17,298 0.02% 2024-06-11
Jay Varma
EVP & Chief Medical Officer, Director
Insider 17,298 0.02% 2024-06-11

Share count 71,855,015 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SIGA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SIGA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.